Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria

Disc Medicine, Inc. (NASDAQ: IRON) has completed dosing the last participant in its pivotal Phase 3 APOLLO trial of bitopertin for erythropoietic protoporphyria (EPP). The study, initially designed for 150 participants, was expanded to 183 due to increased demand from patients and physicians.